Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
about
Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Molecular therapeutic approaches for pediatric acute myeloid leukemia.Life after transplant: are we becoming high maintenance in AML?Precision medicine in pediatric oncology: Lessons learned and next steps.Myelodysplastic Syndromes: Updates and Nuances.Inhibition of FLT3 in AML: a focus on sorafenib.The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia: the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention.Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.The Challenge of t (6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult.Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.
P2860
Q35750567-09E5676C-8E3F-4786-8697-EFA6E6B32C9BQ37638749-945492F0-C5F2-4650-9BB3-F5C78495F8F8Q37643136-9DF43F1D-ED4F-40A0-A01F-6DF73C3DBB13Q38801124-843E5C56-83E3-4516-B557-F9F17739F772Q38810911-89179915-0C2F-41A7-BF56-FD4D72287ED2Q38965973-D064C0E3-2C91-4DD9-9822-07A6C173B88AQ38989349-EAB1D5B2-3B1B-4898-AB69-81BB9805DE85Q39045272-664A02B4-F5CA-491D-911C-D8DF8FE498A1Q39329093-F18B22EF-66AC-4B88-B27C-D7BB22DBF048Q39674948-CF896383-277F-4A36-BD0E-697B3EBEDB94Q40513646-7181D6A4-502E-4F3C-835F-7163578C472AQ42391046-E888765C-C2A3-4783-AA3B-E27C38EA4406Q47150923-90465E78-4ADE-4F44-B6A1-98F8D87F0F3BQ50066002-CF59CD05-934D-42EA-B72F-D30B51D8FFADQ54119583-588C3B1D-8901-4EE0-A469-4D153AB2E13B
P2860
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Sorafenib treatment following ...... T3/ITD acute myeloid leukemia.
@en
Sorafenib treatment following ...... T3/ITD acute myeloid leukemia.
@nl
type
label
Sorafenib treatment following ...... T3/ITD acute myeloid leukemia.
@en
Sorafenib treatment following ...... T3/ITD acute myeloid leukemia.
@nl
prefLabel
Sorafenib treatment following ...... T3/ITD acute myeloid leukemia.
@en
Sorafenib treatment following ...... T3/ITD acute myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1476
Sorafenib treatment following ...... LT3/ITD acute myeloid leukemia
@en
P2093
Ann Woolfrey
Blythe Thomson
Elihu Estey
India Sisler
Jessica A Pollard
Katherine Tarlock
Kathleen Adlard
Phoenix A Ho
Soheil Meshinchi
P2860
P304
P356
10.1002/PBC.25437
P577
2015-02-08T00:00:00Z